Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

被引：1
|
作者：
Piccini, Matteo [1 ]
Pilerci, Sofia [2 ]
Scappini, Barbara [2 ]
Mannelli, Francesco [3 ]
Ciolli, Gaia [4 ]
Pasquini, Andrea [4 ]
Fasano, Laura [4 ]
Quinti, Elisa [4 ]
Guglielmelli, Paola [5 ]
Mannarelli, Carmela [5 ]
Pancani, Fabiana [5 ]
Zizza, Michela [5 ]
Signori, Leonardo [5 ]
Vannucchi, Alessandro M. [6 ]
Gianfaldoni, Giacomo [2 ]
机构：
[1] Univ Firenze, AOU Careggi, SOD Ematol, Florence, Italy
[2] Azienda Osped Univ Careggi, SOD Ematol, Florence, Italy
[3] Azienda Osped Univ Careggi, CRIMM Ctr Res & Innovat Myeloproliferat Neoplasms, SOD Ematol, Florence, Italy
[4] Univ Firenze, Azienda Osped Univ Careggi, Scuola Specializzaz Ematol, SOD Ematol, Florence, Italy
[5] Univ Florence, Ctr Res & Innovat Myeloproliferat Neoplasms, AOU Careggi, CRIMM, Florence, Italy
[6] Univ Firenze, CRIMM Ctr Ric & Innovaz Malattie Mieloproliferat, Azienda Osped Univ Careggi, Florence, Italy
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163212
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
615
引用
收藏
页码：9008 / 9009
页数：2
相关论文
共 50 条
  • [31] Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia
    Zucenka, Andrius
    Griskevicius, Laimonas
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1227 - 1231
  • [32] Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Luo, Tingyue
    Yu, Sijian
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Deng, Lan
    Liang, Xinquan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Shao, Ruoyang
    Du, Xin
    Jin, Hua
    Liu, Qifa
    JOURNAL OF INTERNAL MEDICINE, 2023, 293 (03) : 329 - 339
  • [33] Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Liang, Xinquan
    Deng, Lan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Jin, Hua
    Du, Xin
    Liu, Qifa
    BLOOD, 2022, 140 : 2025 - 2026
  • [34] A retrospective multicenter analysis of low-dose Mephalan in relapsed or refractory acute myeloid leukemia
    van Kann, E.
    Roellig, C.
    Schaich, M.
    Parmentier, S.
    Sebastian, M.
    Chromik, J.
    von Rose, Becker A.
    Ballo, O.
    Steffen, B.
    Serve, H.
    Brandts, C.
    Shaid, S.
    Stratmann, J. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 44 - +
  • [35] Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
    Brancati, Serena
    Gozzo, Lucia
    Romano, Giovanni Luca
    Vetro, Calogero
    Dulcamare, Ilaria
    Maugeri, Cinzia
    Parisi, Marina
    Longo, Laura
    Vitale, Daniela Cristina
    Di Raimondo, Francesco
    Drago, Filippo
    BLOOD, 2021, 138
  • [36] Hypomethylating Agents and Low-Dose Venetoclax for Relapse Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
    Vigil, Carlos Enrique
    Silverman, Margarida
    Carter, Thomas
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S104 - S104
  • [37] Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
    Angotzi, Francesco
    Lessi, Federica
    Leoncin, Matteo
    Fili, Carla
    Endri, Mauro
    Lico, Albana
    Visentin, Andrea
    Pravato, Stefano
    Candoni, Anna
    Trentin, Livio
    Gurrieri, Carmela
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [38] THE USE OF VENETOCLAX WITH HYPOMETHYLATING AGENTS (HMAS) FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN A REAL-LIFE SETTING: THE BOLOGNA EXPERIENCE
    Nanni, J.
    Cristiano, G.
    Marconi, G.
    Parisi, S.
    Sartor, C.
    Ottaviani, E.
    Baldini, L.
    Testoni, N.
    Baldazzi, C.
    Paolini, S.
    Cavo, M.
    Papayannidis, C.
    Curti, A.
    HAEMATOLOGICA, 2019, 104 : 137 - 137
  • [39] Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany
    Braitsch, Krischan
    Schmalbrock, Laura K.
    Jung, Paul
    Bumeder, Irmgard
    Kiewe, Philipp
    Hecker, Judith S.
    Verbeek, Mareike
    Westermann, Joerg
    Bullinger, Lars
    Keller, Ulrich
    Bassermann, Florian
    Kroenke, Jan
    Goetze, Katharina S.
    Rieger, Kathrin
    HEMASPHERE, 2022, 6 (09):
  • [40] USE OF HYPOMETHYLATING AGENTS IN RELAPSED/REFRACTORY PEDIATRIC ACUTE MYELOID LEUKEMIA
    Sabnis, Himalee
    Raikar, Sunil
    Bennett, Anna
    MacDonald, Kelly
    Watkins, Benjamin
    Woods, William
    Keller, Frank
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S52 - S53
12345